pyrimidin-2-one beta-ribofuranoside has been researched along with Medulloblastoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, AF; Borges, KS; Castro-Gamero, AM; Corrêa, CA; de Oliveira, RS; de Vasconcelos, EJ; Dos Santos Aguiar, S; Geron, L; Neder, L; Scrideli, CA; Suazo, VK; Tone, LG; Yunes, JA | 1 |
1 other study(ies) available for pyrimidin-2-one beta-ribofuranoside and Medulloblastoma
| Article | Year |
|---|---|
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Biomarkers; Cell Cycle Proteins; Cell Line, Tumor; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Cytidine; DNA Modification Methylases; Drug Interactions; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Infant, Newborn; Male; Medulloblastoma; Oligonucleotide Array Sequence Analysis; Prognosis; Tumor Suppressor Proteins; Vincristine; Young Adult | 2017 |